 Myron Levin
Concepts (797)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Herpes Zoster | 104 | 2023 | 331 | 18.380 |
Why?
| | Herpes Zoster Vaccine | 64 | 2023 | 159 | 16.840 |
Why?
| | Herpesvirus 3, Human | 85 | 2023 | 378 | 12.630 |
Why?
| | Antibodies, Viral | 64 | 2021 | 520 | 5.310 |
Why?
| | Chickenpox | 23 | 2023 | 93 | 5.130 |
Why?
| | Immunity, Cellular | 35 | 2023 | 248 | 4.730 |
Why?
| | Chickenpox Vaccine | 26 | 2023 | 69 | 3.910 |
Why?
| | Influenza Vaccines | 17 | 2023 | 497 | 2.960 |
Why?
| | HIV Infections | 37 | 2018 | 2469 | 2.730 |
Why?
| | Vaccines, Attenuated | 31 | 2023 | 112 | 2.690 |
Why?
| | Neuralgia, Postherpetic | 18 | 2019 | 44 | 2.560 |
Why?
| | Immunocompromised Host | 13 | 2019 | 195 | 2.530 |
Why?
| | Antiviral Agents | 27 | 2022 | 645 | 2.380 |
Why?
| | Adjuvants, Immunologic | 17 | 2023 | 206 | 2.280 |
Why?
| | Vaccination | 33 | 2023 | 1204 | 2.040 |
Why?
| | Simplexvirus | 23 | 2016 | 80 | 2.030 |
Why?
| | Herpes Simplex | 17 | 2016 | 87 | 2.020 |
Why?
| | Acyclovir | 26 | 2016 | 100 | 1.960 |
Why?
| | DNA, Viral | 24 | 2018 | 350 | 1.850 |
Why?
| | Papillomavirus Vaccines | 13 | 2018 | 223 | 1.750 |
Why?
| | Viral Envelope Proteins | 6 | 2021 | 73 | 1.570 |
Why?
| | Pregnancy Complications, Infectious | 16 | 2020 | 288 | 1.570 |
Why?
| | Herpesvirus 1, Human | 10 | 2016 | 76 | 1.550 |
Why?
| | T-Lymphocytes | 20 | 2019 | 1737 | 1.530 |
Why?
| | Humans | 285 | 2023 | 114698 | 1.530 |
Why?
| | Aged | 91 | 2023 | 19074 | 1.530 |
Why?
| | Aged, 80 and over | 47 | 2022 | 6347 | 1.500 |
Why?
| | Vaccines, Synthetic | 15 | 2023 | 124 | 1.410 |
Why?
| | Antiretroviral Therapy, Highly Active | 13 | 2017 | 256 | 1.400 |
Why?
| | Immunologic Memory | 12 | 2019 | 313 | 1.390 |
Why?
| | Influenza, Human | 12 | 2023 | 546 | 1.380 |
Why?
| | CD4-Positive T-Lymphocytes | 13 | 2023 | 959 | 1.350 |
Why?
| | Immunization, Secondary | 13 | 2017 | 82 | 1.340 |
Why?
| | Papillomavirus Infections | 9 | 2018 | 261 | 1.310 |
Why?
| | Middle Aged | 99 | 2023 | 26738 | 1.310 |
Why?
| | Female | 154 | 2023 | 59520 | 1.210 |
Why?
| | Male | 138 | 2023 | 55606 | 1.160 |
Why?
| | Double-Blind Method | 32 | 2022 | 1660 | 1.110 |
Why?
| | T-Lymphocyte Subsets | 6 | 2019 | 383 | 1.020 |
Why?
| | Incidence | 22 | 2023 | 2313 | 0.960 |
Why?
| | Viral Vaccines | 12 | 2014 | 88 | 0.950 |
Why?
| | Vaccines, Inactivated | 9 | 2023 | 68 | 0.950 |
Why?
| | Chagas Disease | 5 | 2007 | 34 | 0.950 |
Why?
| | CD8-Positive T-Lymphocytes | 5 | 2018 | 687 | 0.920 |
Why?
| | Herpesvirus 2, Human | 6 | 2014 | 27 | 0.900 |
Why?
| | Interferon-gamma | 18 | 2022 | 719 | 0.880 |
Why?
| | Virus Latency | 4 | 2014 | 80 | 0.860 |
Why?
| | Respiratory Syncytial Virus, Human | 3 | 2019 | 60 | 0.860 |
Why?
| | B-Lymphocytes | 9 | 2021 | 766 | 0.860 |
Why?
| | Immune Sera | 4 | 2020 | 79 | 0.850 |
Why?
| | Pneumococcal Vaccines | 3 | 2021 | 131 | 0.830 |
Why?
| | Injections, Intramuscular | 5 | 2022 | 116 | 0.820 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 22 | 2021 | 797 | 0.820 |
Why?
| | Antibodies, Neutralizing | 12 | 2023 | 222 | 0.810 |
Why?
| | Age Factors | 17 | 2021 | 2894 | 0.800 |
Why?
| | Influenza A Virus, H1N1 Subtype | 6 | 2017 | 139 | 0.790 |
Why?
| | Respiratory Syncytial Virus Vaccines | 2 | 2019 | 24 | 0.790 |
Why?
| | Drug Resistance, Viral | 7 | 2009 | 99 | 0.780 |
Why?
| | Antibodies, Protozoan | 3 | 2007 | 30 | 0.780 |
Why?
| | Down Syndrome | 2 | 2023 | 335 | 0.760 |
Why?
| | Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18 | 6 | 2017 | 15 | 0.750 |
Why?
| | Rotavirus Infections | 3 | 2017 | 50 | 0.750 |
Why?
| | Adult | 75 | 2023 | 30553 | 0.730 |
Why?
| | Vaccination Coverage | 2 | 2018 | 63 | 0.730 |
Why?
| | Influenza B virus | 6 | 2012 | 34 | 0.720 |
Why?
| | Anti-Retroviral Agents | 5 | 2018 | 207 | 0.720 |
Why?
| | Infectious Disease Transmission, Vertical | 7 | 2020 | 152 | 0.690 |
Why?
| | Rotavirus Vaccines | 2 | 2017 | 48 | 0.680 |
Why?
| | Adenovirus Infections, Human | 4 | 2015 | 12 | 0.670 |
Why?
| | Clinical Trials as Topic | 15 | 2019 | 932 | 0.670 |
Why?
| | Receptors, Adrenergic, beta-1 | 3 | 2007 | 45 | 0.670 |
Why?
| | Th1 Cells | 3 | 2018 | 123 | 0.640 |
Why?
| | Child, Preschool | 40 | 2023 | 9118 | 0.640 |
Why?
| | Insurance Claim Review | 1 | 2019 | 67 | 0.620 |
Why?
| | HIV | 4 | 2010 | 208 | 0.620 |
Why?
| | Infant | 30 | 2023 | 7964 | 0.620 |
Why?
| | AIDS-Related Opportunistic Infections | 4 | 2015 | 116 | 0.620 |
Why?
| | Influenza A Virus, H3N2 Subtype | 4 | 2017 | 40 | 0.610 |
Why?
| | Alphapapillomavirus | 4 | 2016 | 36 | 0.600 |
Why?
| | Cytomegalovirus Infections | 4 | 2015 | 180 | 0.600 |
Why?
| | Anti-HIV Agents | 6 | 2015 | 666 | 0.600 |
Why?
| | Child | 57 | 2023 | 18420 | 0.590 |
Why?
| | Pneumonia | 1 | 2023 | 568 | 0.590 |
Why?
| | Adolescent | 52 | 2023 | 17853 | 0.590 |
Why?
| | Dose-Response Relationship, Immunologic | 3 | 2016 | 75 | 0.580 |
Why?
| | Trypanosoma cruzi | 4 | 2007 | 23 | 0.580 |
Why?
| | Virus Shedding | 6 | 2017 | 39 | 0.580 |
Why?
| | Health Expenditures | 1 | 2019 | 171 | 0.570 |
Why?
| | Infant, Premature | 5 | 2020 | 476 | 0.570 |
Why?
| | CD4 Lymphocyte Count | 13 | 2017 | 257 | 0.560 |
Why?
| | Antibody Formation | 7 | 2023 | 266 | 0.560 |
Why?
| | Interleukin-2 | 7 | 2022 | 413 | 0.550 |
Why?
| | Pain | 6 | 2022 | 705 | 0.550 |
Why?
| | Herpesviridae Infections | 4 | 2015 | 138 | 0.550 |
Why?
| | Cytosine | 3 | 2015 | 44 | 0.550 |
Why?
| | Antigens, Viral | 21 | 2017 | 176 | 0.530 |
Why?
| | Organophosphonates | 2 | 2015 | 90 | 0.520 |
Why?
| | Immunoglobulin G | 9 | 2021 | 770 | 0.520 |
Why?
| | Injections, Subcutaneous | 1 | 2016 | 134 | 0.520 |
Why?
| | Cytomegalovirus | 7 | 2006 | 144 | 0.520 |
Why?
| | Follow-Up Studies | 21 | 2019 | 4411 | 0.510 |
Why?
| | Enzyme-Linked Immunospot Assay | 4 | 2018 | 34 | 0.500 |
Why?
| | Refrigeration | 2 | 2018 | 11 | 0.490 |
Why?
| | Health Care Costs | 1 | 2018 | 381 | 0.490 |
Why?
| | Uterine Cervical Neoplasms | 5 | 2016 | 216 | 0.490 |
Why?
| | Ribosomal Proteins | 2 | 2006 | 70 | 0.480 |
Why?
| | Polyomavirus Infections | 1 | 2015 | 22 | 0.480 |
Why?
| | Infant, Newborn | 28 | 2023 | 5047 | 0.480 |
Why?
| | Immunity, Humoral | 3 | 2021 | 112 | 0.470 |
Why?
| | Skin Diseases | 1 | 2016 | 122 | 0.470 |
Why?
| | Oropharynx | 1 | 2014 | 36 | 0.470 |
Why?
| | Herpes Genitalis | 7 | 2014 | 16 | 0.460 |
Why?
| | Blood | 1 | 2014 | 96 | 0.460 |
Why?
| | Guanine | 13 | 2006 | 76 | 0.450 |
Why?
| | Viral Load | 11 | 2018 | 405 | 0.450 |
Why?
| | Polymerase Chain Reaction | 10 | 2019 | 993 | 0.440 |
Why?
| | Retrospective Studies | 16 | 2023 | 12555 | 0.440 |
Why?
| | Time Factors | 20 | 2021 | 6116 | 0.440 |
Why?
| | Young Adult | 24 | 2023 | 10471 | 0.440 |
Why?
| | T-Lymphocytes, Regulatory | 1 | 2016 | 339 | 0.430 |
Why?
| | Immunogenicity, Vaccine | 4 | 2022 | 25 | 0.430 |
Why?
| | Vaccines | 3 | 2018 | 375 | 0.430 |
Why?
| | Immunization | 4 | 2014 | 397 | 0.430 |
Why?
| | Aging | 10 | 2017 | 1618 | 0.420 |
Why?
| | Trigeminal Ganglion | 2 | 2003 | 21 | 0.420 |
Why?
| | Herpes Labialis | 3 | 2013 | 8 | 0.420 |
Why?
| | United States | 17 | 2023 | 12186 | 0.410 |
Why?
| | Placebos | 8 | 2017 | 197 | 0.410 |
Why?
| | Sensory Receptor Cells | 1 | 2012 | 77 | 0.400 |
Why?
| | Post-Exposure Prophylaxis | 2 | 2023 | 6 | 0.400 |
Why?
| | Randomized Controlled Trials as Topic | 7 | 2021 | 1214 | 0.400 |
Why?
| | Quality of Life | 7 | 2021 | 2353 | 0.390 |
Why?
| | Communicable Diseases | 1 | 2014 | 129 | 0.390 |
Why?
| | RNA, Viral | 20 | 2018 | 565 | 0.380 |
Why?
| | Pregnancy | 20 | 2020 | 5520 | 0.370 |
Why?
| | Databases, Factual | 4 | 2019 | 1125 | 0.370 |
Why?
| | Induced Pluripotent Stem Cells | 1 | 2012 | 182 | 0.360 |
Why?
| | Risk Factors | 20 | 2023 | 8632 | 0.350 |
Why?
| | Human papillomavirus 18 | 5 | 2018 | 14 | 0.350 |
Why?
| | Glycoproteins | 2 | 2023 | 304 | 0.350 |
Why?
| | Human papillomavirus 16 | 5 | 2018 | 25 | 0.340 |
Why?
| | Treatment Outcome | 19 | 2016 | 9088 | 0.340 |
Why?
| | Poverty | 1 | 2013 | 442 | 0.340 |
Why?
| | Frail Elderly | 2 | 2020 | 106 | 0.320 |
Why?
| | Vaccines, Subunit | 5 | 2021 | 41 | 0.320 |
Why?
| | Immune Reconstitution Inflammatory Syndrome | 1 | 2009 | 18 | 0.320 |
Why?
| | Activities of Daily Living | 3 | 2021 | 349 | 0.310 |
Why?
| | Varicella Zoster Virus Infection | 2 | 2018 | 19 | 0.300 |
Why?
| | Research Design | 2 | 2013 | 928 | 0.290 |
Why?
| | Seasons | 3 | 2023 | 442 | 0.290 |
Why?
| | Neurons | 6 | 2003 | 1280 | 0.290 |
Why?
| | Meningitis, Viral | 3 | 1997 | 21 | 0.290 |
Why?
| | Meningitis | 1 | 2008 | 74 | 0.290 |
Why?
| | Animals | 31 | 2021 | 31708 | 0.290 |
Why?
| | Hemagglutination Inhibition Tests | 7 | 2017 | 37 | 0.290 |
Why?
| | Cytokines | 7 | 2018 | 1841 | 0.280 |
Why?
| | Neoplasms | 3 | 2016 | 2097 | 0.280 |
Why?
| | Viremia | 5 | 2018 | 122 | 0.280 |
Why?
| | Cells, Cultured | 19 | 2012 | 3886 | 0.280 |
Why?
| | Prospective Studies | 24 | 2019 | 6220 | 0.270 |
Why?
| | Respiratory Syncytial Virus Infections | 3 | 2017 | 97 | 0.260 |
Why?
| | Protozoan Proteins | 1 | 2006 | 62 | 0.260 |
Why?
| | Immunocompetence | 4 | 2019 | 40 | 0.260 |
Why?
| | Sleep Wake Disorders | 4 | 2013 | 233 | 0.250 |
Why?
| | Virus Replication | 12 | 2018 | 395 | 0.250 |
Why?
| | Recurrence | 13 | 2019 | 935 | 0.250 |
Why?
| | Nucleic Acid Hybridization | 11 | 2006 | 187 | 0.250 |
Why?
| | Severity of Illness Index | 14 | 2015 | 2540 | 0.250 |
Why?
| | Autoantibodies | 2 | 2007 | 1346 | 0.250 |
Why?
| | Viral Proteins | 5 | 2018 | 281 | 0.240 |
Why?
| | Drug-Related Side Effects and Adverse Reactions | 4 | 2017 | 238 | 0.240 |
Why?
| | Depressive Disorder, Major | 4 | 2013 | 301 | 0.240 |
Why?
| | Cross Reactions | 6 | 2014 | 117 | 0.240 |
Why?
| | Cell Count | 2 | 2005 | 303 | 0.240 |
Why?
| | Intestines | 2 | 2018 | 326 | 0.240 |
Why?
| | Nucleosides | 1 | 2004 | 25 | 0.240 |
Why?
| | Influenza A virus | 5 | 2012 | 90 | 0.240 |
Why?
| | Vaccine Potency | 3 | 2019 | 6 | 0.240 |
Why?
| | Interferons | 9 | 1982 | 151 | 0.230 |
Why?
| | Health Resources | 2 | 2019 | 122 | 0.230 |
Why?
| | Phosphoproteins | 1 | 2006 | 298 | 0.230 |
Why?
| | Nonlinear Dynamics | 1 | 2005 | 83 | 0.230 |
Why?
| | Viral Plaque Assay | 7 | 2012 | 24 | 0.230 |
Why?
| | Herpesvirus 4, Human | 3 | 2014 | 125 | 0.230 |
Why?
| | Monocytes | 7 | 2005 | 504 | 0.220 |
Why?
| | Genetic Variation | 1 | 2008 | 870 | 0.220 |
Why?
| | Neuralgia | 4 | 2010 | 122 | 0.220 |
Why?
| | Immunoassay | 2 | 2017 | 95 | 0.220 |
Why?
| | Developing Countries | 2 | 2016 | 235 | 0.210 |
Why?
| | Antibody Affinity | 2 | 2021 | 52 | 0.210 |
Why?
| | Enterovirus Infections | 5 | 1995 | 160 | 0.210 |
Why?
| | Ganglia, Spinal | 2 | 1993 | 41 | 0.210 |
Why?
| | Encephalitis | 2 | 1995 | 127 | 0.210 |
Why?
| | Drug Combinations | 2 | 2022 | 287 | 0.210 |
Why?
| | Cricetinae | 5 | 2007 | 253 | 0.210 |
Why?
| | Pain Measurement | 8 | 2019 | 444 | 0.200 |
Why?
| | Longitudinal Studies | 8 | 2018 | 2387 | 0.200 |
Why?
| | CHO Cells | 3 | 2007 | 138 | 0.200 |
Why?
| | Lymphocyte Activation | 13 | 2015 | 1037 | 0.200 |
Why?
| | Papillomaviridae | 3 | 2011 | 101 | 0.200 |
Why?
| | Virus Activation | 4 | 2010 | 78 | 0.200 |
Why?
| | Lymphocytosis | 1 | 2021 | 9 | 0.190 |
Why?
| | Fibroblasts | 10 | 2018 | 838 | 0.190 |
Why?
| | Case-Control Studies | 5 | 2018 | 3003 | 0.190 |
Why?
| | Fetal Diseases | 4 | 1991 | 147 | 0.190 |
Why?
| | Immunosenescence | 1 | 2021 | 4 | 0.190 |
Why?
| | Virology | 1 | 2001 | 19 | 0.190 |
Why?
| | Cell Separation | 1 | 2002 | 291 | 0.180 |
Why?
| | Leukemia, Lymphocytic, Chronic, B-Cell | 1 | 2021 | 56 | 0.180 |
Why?
| | Herpes Simplex Virus Vaccines | 2 | 2012 | 3 | 0.180 |
Why?
| | Cohort Studies | 10 | 2022 | 4895 | 0.180 |
Why?
| | HIV-1 | 5 | 2018 | 768 | 0.180 |
Why?
| | Fluorescent Antibody Technique | 6 | 2016 | 397 | 0.180 |
Why?
| | Immunoglobulin A | 3 | 2017 | 166 | 0.180 |
Why?
| | Hemophilia A | 2 | 1993 | 69 | 0.180 |
Why?
| | Antidepressive Agents | 2 | 2013 | 195 | 0.170 |
Why?
| | Health Services for the Aged | 1 | 2001 | 70 | 0.170 |
Why?
| | Enterovirus | 3 | 1995 | 72 | 0.170 |
Why?
| | Myocytes, Cardiac | 1 | 2004 | 449 | 0.170 |
Why?
| | Laboratories | 1 | 2001 | 95 | 0.170 |
Why?
| | Leukocytes, Mononuclear | 5 | 2010 | 493 | 0.170 |
Why?
| | Acquired Immunodeficiency Syndrome | 2 | 1993 | 217 | 0.170 |
Why?
| | Delivery of Health Care, Integrated | 1 | 2022 | 228 | 0.170 |
Why?
| | Immunization, Passive | 4 | 1994 | 73 | 0.170 |
Why?
| | Immunoenzyme Techniques | 3 | 2006 | 192 | 0.170 |
Why?
| | Mice | 9 | 2021 | 14871 | 0.170 |
Why?
| | Pneumococcal Infections | 2 | 2013 | 91 | 0.160 |
Why?
| | Immunization Schedule | 3 | 2016 | 184 | 0.160 |
Why?
| | Liver Transplantation | 1 | 2006 | 707 | 0.160 |
Why?
| | Microbial Sensitivity Tests | 8 | 2005 | 300 | 0.160 |
Why?
| | Cholera Toxin | 1 | 2018 | 27 | 0.160 |
Why?
| | Infant, Premature, Diseases | 3 | 1995 | 89 | 0.160 |
Why?
| | Autophagosomes | 1 | 2018 | 19 | 0.160 |
Why?
| | Lymphocytes | 8 | 1998 | 330 | 0.150 |
Why?
| | Age Distribution | 3 | 2016 | 342 | 0.150 |
Why?
| | Sex Distribution | 3 | 2016 | 337 | 0.150 |
Why?
| | Fatty Acid-Binding Proteins | 1 | 2018 | 60 | 0.150 |
Why?
| | Immune Evasion | 1 | 2018 | 47 | 0.150 |
Why?
| | Drug Therapy, Combination | 4 | 2016 | 951 | 0.150 |
Why?
| | Depression | 3 | 2013 | 1134 | 0.150 |
Why?
| | Viral Fusion Proteins | 1 | 2017 | 20 | 0.150 |
Why?
| | Regression Analysis | 2 | 2019 | 945 | 0.150 |
Why?
| | Lysosomes | 1 | 2018 | 123 | 0.150 |
Why?
| | Genes, Viral | 2 | 2006 | 89 | 0.150 |
Why?
| | Clinical Trials, Phase II as Topic | 1 | 2017 | 59 | 0.150 |
Why?
| | Multivariate Analysis | 2 | 2018 | 1430 | 0.150 |
Why?
| | Models, Biological | 1 | 2005 | 1621 | 0.150 |
Why?
| | Clinical Trials, Phase I as Topic | 1 | 2017 | 45 | 0.150 |
Why?
| | Cost of Illness | 5 | 2014 | 254 | 0.150 |
Why?
| | Lysosomal-Associated Membrane Protein 1 | 1 | 2017 | 5 | 0.140 |
Why?
| | Disease Transmission, Infectious | 1 | 2018 | 55 | 0.140 |
Why?
| | Cryopreservation | 1 | 2018 | 92 | 0.140 |
Why?
| | Protein Subunits | 1 | 2018 | 201 | 0.140 |
Why?
| | Cell Line | 14 | 2018 | 2637 | 0.140 |
Why?
| | Cost-Benefit Analysis | 3 | 2013 | 544 | 0.140 |
Why?
| | Observational Studies as Topic | 1 | 2017 | 90 | 0.140 |
Why?
| | Adverse Drug Reaction Reporting Systems | 1 | 2017 | 68 | 0.140 |
Why?
| | Recombinant Proteins | 2 | 2018 | 1230 | 0.140 |
Why?
| | Infectious Mononucleosis | 2 | 1991 | 8 | 0.140 |
Why?
| | Hospitalization | 2 | 2023 | 1752 | 0.140 |
Why?
| | Receptors, Muscarinic | 1 | 1996 | 17 | 0.140 |
Why?
| | Antibodies, Bacterial | 3 | 2013 | 119 | 0.140 |
Why?
| | Infusions, Intravenous | 2 | 2016 | 371 | 0.140 |
Why?
| | Frailty | 1 | 2019 | 115 | 0.140 |
Why?
| | Africa | 1 | 2017 | 94 | 0.140 |
Why?
| | Receptors, Adrenergic, beta-2 | 1 | 1996 | 39 | 0.140 |
Why?
| | Comorbidity | 3 | 2019 | 1448 | 0.140 |
Why?
| | Foscarnet | 3 | 2003 | 18 | 0.130 |
Why?
| | Nelfinavir | 1 | 2016 | 8 | 0.130 |
Why?
| | Latex Fixation Tests | 1 | 1996 | 3 | 0.130 |
Why?
| | Erythema | 1 | 2016 | 25 | 0.130 |
Why?
| | Autophagy | 1 | 2018 | 235 | 0.130 |
Why?
| | Lopinavir | 1 | 2016 | 29 | 0.130 |
Why?
| | Atazanavir Sulfate | 1 | 2016 | 41 | 0.130 |
Why?
| | Peptide Fragments | 3 | 2007 | 666 | 0.130 |
Why?
| | Hematopoietic Stem Cell Transplantation | 2 | 2015 | 520 | 0.130 |
Why?
| | Antibodies, Monoclonal | 1 | 2022 | 1262 | 0.130 |
Why?
| | HIV Protease Inhibitors | 1 | 2016 | 64 | 0.130 |
Why?
| | Ribavirin | 2 | 1994 | 89 | 0.130 |
Why?
| | Global Health | 1 | 2018 | 287 | 0.130 |
Why?
| | Bone Marrow Transplantation | 3 | 1990 | 239 | 0.130 |
Why?
| | TOR Serine-Threonine Kinases | 1 | 2018 | 360 | 0.130 |
Why?
| | Simian virus 40 | 10 | 1977 | 22 | 0.130 |
Why?
| | Host-Pathogen Interactions | 1 | 2018 | 295 | 0.130 |
Why?
| | Chronic Disease | 6 | 2019 | 1578 | 0.130 |
Why?
| | Ritonavir | 1 | 2016 | 71 | 0.130 |
Why?
| | Programmed Cell Death 1 Receptor | 1 | 2017 | 194 | 0.120 |
Why?
| | Dipeptides | 1 | 2015 | 48 | 0.120 |
Why?
| | Reproducibility of Results | 5 | 2013 | 2765 | 0.120 |
Why?
| | Survival Rate | 3 | 2016 | 1644 | 0.120 |
Why?
| | Guatemala | 1 | 2016 | 266 | 0.120 |
Why?
| | Lymphocyte Subsets | 1 | 2015 | 79 | 0.120 |
Why?
| | Data Interpretation, Statistical | 3 | 2019 | 321 | 0.120 |
Why?
| | BK Virus | 1 | 2015 | 14 | 0.120 |
Why?
| | Brain Stem | 1 | 1995 | 101 | 0.120 |
Why?
| | Propylene Glycols | 1 | 2015 | 25 | 0.120 |
Why?
| | Molecular Sequence Data | 5 | 2006 | 2785 | 0.120 |
Why?
| | Medication Reconciliation | 1 | 2015 | 25 | 0.120 |
Why?
| | Sphingosine | 1 | 2015 | 33 | 0.120 |
Why?
| | Base Sequence | 8 | 2007 | 2114 | 0.120 |
Why?
| | Infant, Newborn, Diseases | 1 | 2016 | 104 | 0.120 |
Why?
| | Histocompatibility Antigens Class I | 1 | 1996 | 172 | 0.120 |
Why?
| | Respiratory Syncytial Viruses | 4 | 1993 | 46 | 0.120 |
Why?
| | Immunity, Mucosal | 2 | 2012 | 84 | 0.120 |
Why?
| | Feces | 1 | 2017 | 373 | 0.120 |
Why?
| | Maternal-Fetal Exchange | 3 | 1995 | 151 | 0.120 |
Why?
| | Chlamydia trachomatis | 2 | 1991 | 36 | 0.120 |
Why?
| | Lymphoma | 1 | 2015 | 177 | 0.120 |
Why?
| | Maus Elberfeld virus | 2 | 1991 | 5 | 0.120 |
Why?
| | Transfusion Reaction | 1 | 1995 | 65 | 0.120 |
Why?
| | Clinical Trials, Phase III as Topic | 3 | 2021 | 82 | 0.120 |
Why?
| | Placenta | 2 | 1991 | 628 | 0.120 |
Why?
| | Needs Assessment | 1 | 2016 | 314 | 0.120 |
Why?
| | Laryngeal Diseases | 1 | 1994 | 21 | 0.110 |
Why?
| | Hemagglutinins, Viral | 1 | 1994 | 6 | 0.110 |
Why?
| | Cross-Over Studies | 2 | 2013 | 440 | 0.110 |
Why?
| | DNA-Directed DNA Polymerase | 2 | 1992 | 44 | 0.110 |
Why?
| | Analgesics | 3 | 2010 | 158 | 0.110 |
Why?
| | Autoantigens | 1 | 1996 | 396 | 0.110 |
Why?
| | Lamivudine | 2 | 2015 | 59 | 0.110 |
Why?
| | Practice Guidelines as Topic | 2 | 2017 | 1395 | 0.110 |
Why?
| | Zidovudine | 2 | 2015 | 77 | 0.110 |
Why?
| | Immunoglobulins, Intravenous | 5 | 1995 | 122 | 0.110 |
Why?
| | Anti-Inflammatory Agents | 3 | 2013 | 447 | 0.110 |
Why?
| | Controlled Clinical Trials as Topic | 1 | 2013 | 27 | 0.110 |
Why?
| | Autoimmune Diseases | 1 | 1996 | 382 | 0.110 |
Why?
| | Health Status | 2 | 2010 | 722 | 0.110 |
Why?
| | Indoles | 1 | 2015 | 304 | 0.110 |
Why?
| | Risk Assessment | 4 | 2016 | 2968 | 0.110 |
Why?
| | Ethics, Research | 1 | 2013 | 34 | 0.110 |
Why?
| | Research Subjects | 1 | 2013 | 40 | 0.110 |
Why?
| | Precursor Cell Lymphoblastic Leukemia-Lymphoma | 1 | 1996 | 256 | 0.100 |
Why?
| | Immunosuppressive Agents | 3 | 2015 | 646 | 0.100 |
Why?
| | Killer Cells, Natural | 1 | 1996 | 380 | 0.100 |
Why?
| | Epitopes, T-Lymphocyte | 1 | 2014 | 170 | 0.100 |
Why?
| | Picornaviridae Infections | 2 | 1990 | 29 | 0.100 |
Why?
| | RNA Probes | 2 | 1991 | 13 | 0.100 |
Why?
| | Chagas Cardiomyopathy | 2 | 2007 | 22 | 0.100 |
Why?
| | Colorado | 4 | 2018 | 4100 | 0.100 |
Why?
| | Measles Vaccine | 1 | 2012 | 17 | 0.100 |
Why?
| | Gene Expression Regulation, Viral | 1 | 2012 | 80 | 0.100 |
Why?
| | Flow Cytometry | 5 | 2017 | 1083 | 0.100 |
Why?
| | Cell Division | 4 | 2003 | 758 | 0.100 |
Why?
| | Macrophages | 3 | 2005 | 1263 | 0.100 |
Why?
| | Health Services Accessibility | 1 | 2018 | 763 | 0.100 |
Why?
| | Human papillomavirus 31 | 1 | 2011 | 1 | 0.100 |
Why?
| | Drug Resistance, Microbial | 4 | 2001 | 66 | 0.100 |
Why?
| | Mutation | 5 | 2009 | 3346 | 0.100 |
Why?
| | Ureaplasma urealyticum | 1 | 1991 | 3 | 0.100 |
Why?
| | Meningitis, Aseptic | 1 | 1991 | 15 | 0.100 |
Why?
| | Insurance, Health | 1 | 2014 | 244 | 0.100 |
Why?
| | T-Lymphocytes, Cytotoxic | 2 | 2011 | 154 | 0.100 |
Why?
| | Neurogenesis | 1 | 2012 | 102 | 0.100 |
Why?
| | Myocardium | 1 | 1996 | 913 | 0.100 |
Why?
| | Neural Stem Cells | 1 | 2012 | 115 | 0.090 |
Why?
| | Chorioamnionitis | 1 | 1991 | 36 | 0.090 |
Why?
| | Linear Models | 2 | 2010 | 768 | 0.090 |
Why?
| | Efficiency | 1 | 2012 | 84 | 0.090 |
Why?
| | Cytotoxicity Tests, Immunologic | 2 | 1996 | 43 | 0.090 |
Why?
| | Sensitivity and Specificity | 3 | 2009 | 1693 | 0.090 |
Why?
| | Gastroenteritis | 2 | 1989 | 65 | 0.090 |
Why?
| | Drug Design | 1 | 2012 | 148 | 0.090 |
Why?
| | Epidemiological Monitoring | 3 | 2018 | 47 | 0.090 |
Why?
| | Cervix Uteri | 1 | 2010 | 45 | 0.090 |
Why?
| | Adjuvants, Pharmaceutic | 2 | 2022 | 10 | 0.090 |
Why?
| | Rats | 3 | 2006 | 4958 | 0.090 |
Why?
| | Genotype | 2 | 2008 | 1760 | 0.090 |
Why?
| | Surveys and Questionnaires | 7 | 2021 | 4624 | 0.090 |
Why?
| | Exanthema | 1 | 2011 | 74 | 0.090 |
Why?
| | Serum | 1 | 2010 | 57 | 0.090 |
Why?
| | Herpesviridae | 2 | 1981 | 21 | 0.090 |
Why?
| | Pilot Projects | 1 | 2015 | 1373 | 0.090 |
Why?
| | Respiratory Tract Infections | 1 | 1994 | 319 | 0.090 |
Why?
| | Antidepressive Agents, Tricyclic | 1 | 2010 | 29 | 0.090 |
Why?
| | Herpesvirus Vaccines | 1 | 2010 | 4 | 0.090 |
Why?
| | Immunoglobulin M | 1 | 1991 | 246 | 0.090 |
Why?
| | Antigen-Presenting Cells | 5 | 2010 | 150 | 0.090 |
Why?
| | Enterovirus B, Human | 2 | 1988 | 24 | 0.080 |
Why?
| | Medicaid | 1 | 2014 | 407 | 0.080 |
Why?
| | Dermatomyositis | 1 | 1989 | 23 | 0.080 |
Why?
| | Epitopes | 3 | 2004 | 435 | 0.080 |
Why?
| | Poliovirus | 2 | 2001 | 77 | 0.080 |
Why?
| | Receptors, Virus | 2 | 2006 | 75 | 0.080 |
Why?
| | Hepatitis B Vaccines | 1 | 2009 | 46 | 0.080 |
Why?
| | Geriatrics | 1 | 2010 | 69 | 0.080 |
Why?
| | Placenta Diseases | 1 | 1989 | 13 | 0.080 |
Why?
| | Protozoan Infections | 1 | 1989 | 10 | 0.080 |
Why?
| | Drug Stability | 1 | 2009 | 151 | 0.080 |
Why?
| | Vagina | 1 | 2010 | 146 | 0.080 |
Why?
| | Thymidine Kinase | 4 | 2001 | 14 | 0.080 |
Why?
| | DNA Primers | 2 | 2009 | 510 | 0.080 |
Why?
| | Skin Diseases, Viral | 1 | 2008 | 4 | 0.080 |
Why?
| | Oligonucleotide Probes | 1 | 1988 | 54 | 0.080 |
Why?
| | Hydrocortisone | 1 | 2010 | 267 | 0.080 |
Why?
| | Immunologic Deficiency Syndromes | 2 | 1986 | 61 | 0.080 |
Why?
| | Geriatric Assessment | 1 | 2010 | 176 | 0.080 |
Why?
| | Acute Kidney Injury | 1 | 2015 | 638 | 0.080 |
Why?
| | Species Specificity | 2 | 2006 | 542 | 0.080 |
Why?
| | Kinetics | 2 | 2010 | 1551 | 0.080 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 1 | 1996 | 1355 | 0.080 |
Why?
| | Amino Acid Sequence | 2 | 2006 | 1982 | 0.080 |
Why?
| | Anticonvulsants | 1 | 2010 | 179 | 0.080 |
Why?
| | Administration, Intranasal | 1 | 2008 | 75 | 0.080 |
Why?
| | Interferon Type I | 1 | 1989 | 128 | 0.080 |
Why?
| | Muscles | 1 | 1989 | 320 | 0.080 |
Why?
| | Evidence-Based Practice | 1 | 2010 | 185 | 0.080 |
Why?
| | Prevalence | 4 | 2018 | 2251 | 0.080 |
Why?
| | In Vitro Techniques | 6 | 2003 | 1016 | 0.070 |
Why?
| | Poisson Distribution | 2 | 2005 | 71 | 0.070 |
Why?
| | Sequence Alignment | 1 | 2008 | 323 | 0.070 |
Why?
| | Picornaviridae | 1 | 1988 | 17 | 0.070 |
Why?
| | Lipid A | 2 | 2018 | 28 | 0.070 |
Why?
| | Enterocolitis, Pseudomembranous | 1 | 1988 | 25 | 0.070 |
Why?
| | Pertussis Vaccine | 1 | 2007 | 21 | 0.070 |
Why?
| | Veterans | 1 | 2018 | 1249 | 0.070 |
Why?
| | Pregnancy Outcome | 1 | 2010 | 337 | 0.070 |
Why?
| | Spinal Cord | 2 | 2001 | 347 | 0.070 |
Why?
| | Public Health | 1 | 2012 | 434 | 0.070 |
Why?
| | Immunosorbent Techniques | 1 | 2007 | 17 | 0.070 |
Why?
| | Quality-Adjusted Life Years | 1 | 2007 | 101 | 0.070 |
Why?
| | Data Collection | 1 | 2010 | 620 | 0.070 |
Why?
| | Cricetulus | 1 | 2007 | 97 | 0.070 |
Why?
| | Receptor, IGF Type 2 | 1 | 2006 | 7 | 0.070 |
Why?
| | Adenoviridae | 8 | 2005 | 184 | 0.070 |
Why?
| | Vero Cells | 1 | 2006 | 63 | 0.070 |
Why?
| | Inhibitory Concentration 50 | 1 | 2006 | 74 | 0.070 |
Why?
| | COS Cells | 1 | 2007 | 175 | 0.070 |
Why?
| | Research | 1 | 2010 | 394 | 0.070 |
Why?
| | Heparitin Sulfate | 1 | 2006 | 39 | 0.070 |
Why?
| | Opportunistic Infections | 3 | 1993 | 43 | 0.070 |
Why?
| | Neutralization Tests | 5 | 2012 | 63 | 0.070 |
Why?
| | Immunoglobulin Fragments | 1 | 2006 | 15 | 0.070 |
Why?
| | NIH 3T3 Cells | 1 | 2006 | 137 | 0.070 |
Why?
| | Drug Administration Schedule | 2 | 2021 | 718 | 0.070 |
Why?
| | Administration, Topical | 4 | 2013 | 138 | 0.070 |
Why?
| | Kaplan-Meier Estimate | 3 | 2016 | 811 | 0.070 |
Why?
| | Cyclic AMP | 1 | 2007 | 227 | 0.070 |
Why?
| | Random Allocation | 6 | 1992 | 335 | 0.070 |
Why?
| | Immunoglobulin Variable Region | 1 | 2006 | 72 | 0.070 |
Why?
| | Meningococcal Vaccines | 1 | 2006 | 48 | 0.070 |
Why?
| | Logistic Models | 2 | 2010 | 1841 | 0.070 |
Why?
| | Antineoplastic Agents | 2 | 2016 | 1879 | 0.060 |
Why?
| | Pneumonia, Viral | 2 | 1990 | 338 | 0.060 |
Why?
| | Nasopharyngeal Diseases | 1 | 1985 | 5 | 0.060 |
Why?
| | Bone Marrow | 2 | 1984 | 243 | 0.060 |
Why?
| | Proportional Hazards Models | 1 | 2009 | 1075 | 0.060 |
Why?
| | Endocytosis | 1 | 2006 | 148 | 0.060 |
Why?
| | Motor Activity | 1 | 2010 | 640 | 0.060 |
Why?
| | Cell Differentiation | 1 | 2012 | 1701 | 0.060 |
Why?
| | Organ Transplantation | 1 | 2008 | 159 | 0.060 |
Why?
| | Flaviviridae Infections | 1 | 2005 | 1 | 0.060 |
Why?
| | GB virus C | 1 | 2005 | 1 | 0.060 |
Why?
| | Hydrogen-Ion Concentration | 1 | 2006 | 511 | 0.060 |
Why?
| | Hepatitis, Viral, Human | 1 | 2005 | 25 | 0.060 |
Why?
| | Disease Outbreaks | 1 | 1988 | 307 | 0.060 |
Why?
| | HLA Antigens | 3 | 1987 | 225 | 0.060 |
Why?
| | Normal Distribution | 1 | 2005 | 19 | 0.060 |
Why?
| | Mental Health | 1 | 2010 | 562 | 0.060 |
Why?
| | Uterine Cervical Dysplasia | 2 | 2016 | 42 | 0.060 |
Why?
| | Evaluation Studies as Topic | 3 | 1996 | 167 | 0.060 |
Why?
| | Transfection | 1 | 2007 | 866 | 0.060 |
Why?
| | Autopsy | 2 | 2001 | 84 | 0.060 |
Why?
| | Neurons, Afferent | 1 | 2005 | 85 | 0.060 |
Why?
| | Hybridization, Genetic | 8 | 1974 | 78 | 0.060 |
Why?
| | Sex Factors | 2 | 2003 | 1715 | 0.060 |
Why?
| | Cell Culture Techniques | 1 | 2006 | 343 | 0.060 |
Why?
| | Risk | 3 | 2016 | 812 | 0.060 |
Why?
| | Receptors, Cholinergic | 1 | 2004 | 41 | 0.060 |
Why?
| | Macaca radiata | 2 | 2001 | 16 | 0.060 |
Why?
| | Epitope Mapping | 1 | 2004 | 51 | 0.060 |
Why?
| | Dose-Response Relationship, Drug | 3 | 2015 | 1842 | 0.060 |
Why?
| | Cell Adhesion Molecules | 1 | 2005 | 168 | 0.060 |
Why?
| | RNA | 2 | 1988 | 809 | 0.060 |
Why?
| | Abdominal Neoplasms | 1 | 2003 | 26 | 0.060 |
Why?
| | Polymorphism, Restriction Fragment Length | 1 | 2003 | 65 | 0.060 |
Why?
| | Receptors, Cell Surface | 1 | 2005 | 355 | 0.050 |
Why?
| | Receptors, Adrenergic, beta | 1 | 2004 | 127 | 0.050 |
Why?
| | Demography | 2 | 2018 | 260 | 0.050 |
Why?
| | Membrane Glycoproteins | 1 | 2005 | 430 | 0.050 |
Why?
| | Polymorphism, Single Nucleotide | 2 | 2009 | 1880 | 0.050 |
Why?
| | 2-Aminopurine | 2 | 2007 | 10 | 0.050 |
Why?
| | Adaptive Immunity | 2 | 2017 | 155 | 0.050 |
Why?
| | Heart Rate | 1 | 2006 | 709 | 0.050 |
Why?
| | Neuroblastoma | 1 | 2003 | 133 | 0.050 |
Why?
| | Poliomyelitis | 2 | 2001 | 27 | 0.050 |
Why?
| | Forecasting | 3 | 2010 | 330 | 0.050 |
Why?
| | Cell Nucleus | 3 | 1991 | 554 | 0.050 |
Why?
| | Blotting, Western | 2 | 2015 | 1147 | 0.050 |
Why?
| | Hepatitis C | 1 | 2004 | 219 | 0.050 |
Why?
| | Gene Expression | 1 | 2006 | 1421 | 0.050 |
Why?
| | Genome, Viral | 1 | 2002 | 118 | 0.050 |
Why?
| | Poliovirus Vaccine, Oral | 1 | 2001 | 19 | 0.050 |
Why?
| | Spondylarthropathies | 1 | 2021 | 6 | 0.050 |
Why?
| | Respirovirus Infections | 2 | 1991 | 21 | 0.050 |
Why?
| | Sex Characteristics | 2 | 2017 | 641 | 0.050 |
Why?
| | Heart Transplantation | 1 | 2007 | 665 | 0.050 |
Why?
| | Sleep | 1 | 2006 | 632 | 0.050 |
Why?
| | Peripheral Nerves | 1 | 2001 | 64 | 0.050 |
Why?
| | Fatal Outcome | 1 | 2001 | 284 | 0.050 |
Why?
| | Secondary Prevention | 2 | 2013 | 222 | 0.050 |
Why?
| | Virion | 1 | 2001 | 73 | 0.040 |
Why?
| | Psoriasis | 1 | 2021 | 74 | 0.040 |
Why?
| | Canada | 2 | 2012 | 322 | 0.040 |
Why?
| | Amniotic Fluid | 3 | 1991 | 64 | 0.040 |
Why?
| | Enterotoxins | 2 | 1994 | 88 | 0.040 |
Why?
| | Rats, Sprague-Dawley | 1 | 2004 | 2218 | 0.040 |
Why?
| | Hematopoietic Stem Cells | 1 | 1982 | 343 | 0.040 |
Why?
| | Saliva | 2 | 2010 | 188 | 0.040 |
Why?
| | Saponins | 1 | 2018 | 6 | 0.040 |
Why?
| | Haptoglobins | 1 | 2018 | 47 | 0.040 |
Why?
| | Seroconversion | 1 | 2018 | 45 | 0.040 |
Why?
| | Encephalitis, Viral | 1 | 1998 | 39 | 0.040 |
Why?
| | Drug Compounding | 1 | 2018 | 89 | 0.040 |
Why?
| | Celiac Disease | 1 | 2021 | 264 | 0.040 |
Why?
| | Protein Precursors | 1 | 2018 | 119 | 0.040 |
Why?
| | Biomarkers | 2 | 2018 | 3408 | 0.040 |
Why?
| | Glucosides | 1 | 2017 | 36 | 0.040 |
Why?
| | Immunologic Techniques | 2 | 1994 | 39 | 0.040 |
Why?
| | Health Surveys | 1 | 2019 | 443 | 0.040 |
Why?
| | Sterols | 1 | 2017 | 17 | 0.040 |
Why?
| | Inositol Phosphates | 1 | 2017 | 23 | 0.040 |
Why?
| | Patient Safety | 1 | 2020 | 277 | 0.040 |
Why?
| | Botswana | 1 | 2017 | 7 | 0.040 |
Why?
| | International Cooperation | 1 | 2018 | 171 | 0.040 |
Why?
| | Internationality | 1 | 2018 | 143 | 0.040 |
Why?
| | Antigens, Bacterial | 1 | 2017 | 112 | 0.040 |
Why?
| | Zimbabwe | 1 | 2017 | 42 | 0.040 |
Why?
| | Recovery of Function | 1 | 2021 | 574 | 0.040 |
Why?
| | Tanzania | 1 | 2017 | 41 | 0.040 |
Why?
| | Chemotaxis | 1 | 2017 | 130 | 0.030 |
Why?
| | Bisoprolol | 1 | 1996 | 4 | 0.030 |
Why?
| | Plasma | 1 | 2018 | 211 | 0.030 |
Why?
| | Zambia | 1 | 2017 | 69 | 0.030 |
Why?
| | Sinusitis | 1 | 1999 | 174 | 0.030 |
Why?
| | Cross-Sectional Studies | 4 | 2011 | 4410 | 0.030 |
Why?
| | Immune Tolerance | 4 | 1998 | 323 | 0.030 |
Why?
| | Acute Disease | 2 | 2011 | 911 | 0.030 |
Why?
| | Cerebrospinal Fluid | 2 | 1993 | 90 | 0.030 |
Why?
| | Leukemia, Lymphoid | 2 | 1986 | 27 | 0.030 |
Why?
| | Propanolamines | 1 | 1996 | 90 | 0.030 |
Why?
| | Predictive Value of Tests | 2 | 2010 | 1796 | 0.030 |
Why?
| | False Negative Reactions | 1 | 1996 | 48 | 0.030 |
Why?
| | Public Health Surveillance | 1 | 2016 | 61 | 0.030 |
Why?
| | False Positive Reactions | 1 | 1996 | 109 | 0.030 |
Why?
| | Amniocentesis | 2 | 1991 | 21 | 0.030 |
Why?
| | Depressive Disorder | 1 | 1998 | 332 | 0.030 |
Why?
| | Gene Regulatory Networks | 1 | 2017 | 228 | 0.030 |
Why?
| | Inhibitor of Apoptosis Proteins | 1 | 2015 | 42 | 0.030 |
Why?
| | Half-Life | 2 | 1992 | 141 | 0.030 |
Why?
| | AIDS Dementia Complex | 1 | 2015 | 50 | 0.030 |
Why?
| | Nevirapine | 1 | 2015 | 16 | 0.030 |
Why?
| | Analysis of Variance | 2 | 2011 | 1226 | 0.030 |
Why?
| | Nausea | 1 | 2015 | 101 | 0.030 |
Why?
| | Breast Feeding | 1 | 2018 | 368 | 0.030 |
Why?
| | Chi-Square Distribution | 2 | 2013 | 493 | 0.030 |
Why?
| | Vomiting | 1 | 2015 | 123 | 0.030 |
Why?
| | Area Under Curve | 1 | 2015 | 274 | 0.030 |
Why?
| | Fingolimod Hydrochloride | 1 | 2015 | 29 | 0.030 |
Why?
| | Bromodeoxyuridine | 2 | 2007 | 72 | 0.030 |
Why?
| | Disease Susceptibility | 1 | 1996 | 316 | 0.030 |
Why?
| | Neutropenia | 1 | 2015 | 125 | 0.030 |
Why?
| | Adrenergic beta-Antagonists | 1 | 1996 | 287 | 0.030 |
Why?
| | Product Surveillance, Postmarketing | 1 | 2015 | 63 | 0.030 |
Why?
| | Headache | 1 | 2015 | 133 | 0.030 |
Why?
| | Belgium | 1 | 2014 | 11 | 0.030 |
Why?
| | Vaccines, Virus-Like Particle | 1 | 2014 | 3 | 0.030 |
Why?
| | Metabolic Diseases | 1 | 2015 | 98 | 0.030 |
Why?
| | Culture Media | 2 | 1984 | 155 | 0.030 |
Why?
| | HLA-A2 Antigen | 1 | 2014 | 36 | 0.030 |
Why?
| | Rubella | 1 | 1974 | 21 | 0.030 |
Why?
| | Hemagglutinin Glycoproteins, Influenza Virus | 1 | 1994 | 20 | 0.030 |
Why?
| | Probability | 2 | 2005 | 289 | 0.030 |
Why?
| | Tetanus Toxoid | 1 | 1994 | 37 | 0.030 |
Why?
| | Immunoblotting | 1 | 1994 | 283 | 0.030 |
Why?
| | Anemia | 1 | 2015 | 143 | 0.030 |
Why?
| | Drugs, Investigational | 1 | 2014 | 30 | 0.030 |
Why?
| | Seroepidemiologic Studies | 1 | 2014 | 138 | 0.030 |
Why?
| | Statistics, Nonparametric | 2 | 2004 | 385 | 0.030 |
Why?
| | Mortality | 1 | 2015 | 287 | 0.030 |
Why?
| | Thrombocytopenia | 1 | 2015 | 177 | 0.030 |
Why?
| | Developed Countries | 1 | 2013 | 28 | 0.030 |
Why?
| | Arthritis, Rheumatoid | 1 | 2021 | 1003 | 0.030 |
Why?
| | Early Detection of Cancer | 1 | 2016 | 328 | 0.030 |
Why?
| | Skin | 2 | 1989 | 655 | 0.030 |
Why?
| | Metabolomics | 1 | 2017 | 521 | 0.030 |
Why?
| | Consensus | 1 | 2015 | 537 | 0.030 |
Why?
| | Drug Tolerance | 1 | 1992 | 79 | 0.020 |
Why?
| | Human papillomavirus 6 | 1 | 2011 | 2 | 0.020 |
Why?
| | Ureaplasma Infections | 1 | 1991 | 3 | 0.020 |
Why?
| | Inflammation | 2 | 2017 | 2480 | 0.020 |
Why?
| | Safety | 1 | 1994 | 298 | 0.020 |
Why?
| | Mycoplasma Infections | 1 | 1991 | 13 | 0.020 |
Why?
| | Genitalia, Female | 1 | 2012 | 37 | 0.020 |
Why?
| | gamma-Globulins | 1 | 1991 | 18 | 0.020 |
Why?
| | Epstein-Barr Virus Nuclear Antigens | 1 | 1991 | 8 | 0.020 |
Why?
| | Antibodies, Heterophile | 1 | 1991 | 13 | 0.020 |
Why?
| | Absenteeism | 1 | 2012 | 40 | 0.020 |
Why?
| | Adenoviruses, Human | 1 | 1991 | 24 | 0.020 |
Why?
| | Adrenal Cortex Hormones | 1 | 2015 | 497 | 0.020 |
Why?
| | Drug Resistance, Neoplasm | 1 | 2015 | 636 | 0.020 |
Why?
| | Hospitals, University | 1 | 1991 | 172 | 0.020 |
Why?
| | Diagnosis, Differential | 3 | 2009 | 1342 | 0.020 |
Why?
| | Matched-Pair Analysis | 1 | 2011 | 33 | 0.020 |
Why?
| | Europe | 1 | 2012 | 334 | 0.020 |
Why?
| | North America | 1 | 2012 | 256 | 0.020 |
Why?
| | Bodily Secretions | 1 | 2010 | 2 | 0.020 |
Why?
| | Cell Proliferation | 1 | 2018 | 2187 | 0.020 |
Why?
| | Paramyxoviridae Infections | 1 | 1990 | 10 | 0.020 |
Why?
| | Chlamydia Infections | 1 | 1991 | 65 | 0.020 |
Why?
| | Rhinovirus | 1 | 1990 | 40 | 0.020 |
Why?
| | Bacterial Infections | 2 | 2001 | 218 | 0.020 |
Why?
| | Schwann Cells | 1 | 1990 | 27 | 0.020 |
Why?
| | Antigens | 2 | 1970 | 318 | 0.020 |
Why?
| | DNA | 4 | 1988 | 1352 | 0.020 |
Why?
| | Gene Expression Profiling | 1 | 2017 | 1518 | 0.020 |
Why?
| | Gestational Age | 2 | 1989 | 760 | 0.020 |
Why?
| | Prenatal Exposure Delayed Effects | 1 | 2016 | 452 | 0.020 |
Why?
| | Antigens, Surface | 2 | 1987 | 146 | 0.020 |
Why?
| | Serotyping | 2 | 1988 | 28 | 0.020 |
Why?
| | Health Planning Guidelines | 1 | 2010 | 25 | 0.020 |
Why?
| | Self Administration | 1 | 2010 | 122 | 0.020 |
Why?
| | Hepatitis B Antibodies | 1 | 2009 | 10 | 0.020 |
Why?
| | Haplorhini | 7 | 1974 | 57 | 0.020 |
Why?
| | beta-Globins | 1 | 2009 | 10 | 0.020 |
Why?
| | In Situ Hybridization | 2 | 2001 | 292 | 0.020 |
Why?
| | Contraceptive Devices, Male | 1 | 1989 | 1 | 0.020 |
Why?
| | Subacute Sclerosing Panencephalitis | 1 | 1989 | 5 | 0.020 |
Why?
| | Spermatocidal Agents | 1 | 1989 | 5 | 0.020 |
Why?
| | Reference Values | 1 | 2011 | 743 | 0.020 |
Why?
| | Ribonucleosides | 1 | 1989 | 5 | 0.020 |
Why?
| | Disease Progression | 1 | 2016 | 2380 | 0.020 |
Why?
| | Physical Examination | 1 | 2010 | 222 | 0.020 |
Why?
| | Immunohistochemistry | 1 | 1993 | 1629 | 0.020 |
Why?
| | Astrocytes | 1 | 1990 | 162 | 0.020 |
Why?
| | Thymidine | 4 | 1980 | 58 | 0.020 |
Why?
| | Nasal Mucosa | 1 | 2009 | 93 | 0.020 |
Why?
| | RNA, Antisense | 1 | 1988 | 17 | 0.020 |
Why?
| | Reference Standards | 1 | 2009 | 159 | 0.020 |
Why?
| | Measles | 1 | 1989 | 38 | 0.020 |
Why?
| | Virus Cultivation | 4 | 1984 | 25 | 0.020 |
Why?
| | Mammalian orthoreovirus 3 | 1 | 1988 | 34 | 0.020 |
Why?
| | Fetus | 1 | 1992 | 700 | 0.020 |
Why?
| | Reoviridae | 1 | 1988 | 35 | 0.020 |
Why?
| | Cancer Vaccines | 1 | 2009 | 137 | 0.020 |
Why?
| | Hepatitis | 1 | 1988 | 45 | 0.020 |
Why?
| | DNA, Recombinant | 1 | 1988 | 41 | 0.020 |
Why?
| | Health Services Needs and Demand | 1 | 2010 | 243 | 0.020 |
Why?
| | Reoviridae Infections | 1 | 1988 | 52 | 0.020 |
Why?
| | Neoplasms, Experimental | 1 | 1969 | 151 | 0.020 |
Why?
| | Telomere | 1 | 2010 | 202 | 0.020 |
Why?
| | Sequence Homology, Nucleic Acid | 1 | 1988 | 152 | 0.020 |
Why?
| | Cytopathogenic Effect, Viral | 2 | 1982 | 15 | 0.020 |
Why?
| | Body Fluids | 1 | 1987 | 58 | 0.020 |
Why?
| | Cell Transformation, Neoplastic | 4 | 1977 | 308 | 0.020 |
Why?
| | Australia | 1 | 2008 | 206 | 0.020 |
Why?
| | Anti-Bacterial Agents | 2 | 1999 | 1481 | 0.020 |
Why?
| | Mass Screening | 1 | 2014 | 1005 | 0.020 |
Why?
| | Tritium | 6 | 1974 | 66 | 0.020 |
Why?
| | Gastrointestinal Hemorrhage | 1 | 1988 | 102 | 0.020 |
Why?
| | Noma | 1 | 1986 | 2 | 0.020 |
Why?
| | Heptavalent Pneumococcal Conjugate Vaccine | 1 | 2006 | 11 | 0.020 |
Why?
| | Valine | 1 | 2007 | 72 | 0.020 |
Why?
| | Apoptosis | 1 | 2015 | 2363 | 0.020 |
Why?
| | Open Reading Frames | 1 | 2007 | 117 | 0.020 |
Why?
| | Residence Characteristics | 1 | 2008 | 275 | 0.020 |
Why?
| | Biliary Atresia | 1 | 1988 | 185 | 0.020 |
Why?
| | Amino Acid Substitution | 1 | 2007 | 262 | 0.020 |
Why?
| | Interleukin-4 | 2 | 1998 | 206 | 0.020 |
Why?
| | Biopsy | 1 | 1989 | 1036 | 0.020 |
Why?
| | Ketones | 1 | 1986 | 44 | 0.020 |
Why?
| | Intensive Care Units, Neonatal | 1 | 1988 | 176 | 0.020 |
Why?
| | Reagent Kits, Diagnostic | 1 | 1985 | 42 | 0.020 |
Why?
| | Statistics as Topic | 1 | 2006 | 292 | 0.020 |
Why?
| | Nectins | 1 | 2005 | 4 | 0.020 |
Why?
| | Streptococcus pneumoniae | 1 | 2006 | 133 | 0.020 |
Why?
| | Lymphoproliferative Disorders | 1 | 1985 | 46 | 0.020 |
Why?
| | California | 1 | 2006 | 353 | 0.020 |
Why?
| | Factor Analysis, Statistical | 1 | 2006 | 257 | 0.020 |
Why?
| | Toll-Like Receptor 2 | 1 | 2005 | 110 | 0.010 |
Why?
| | Cytotoxicity, Immunologic | 1 | 1985 | 195 | 0.010 |
Why?
| | Toll-Like Receptors | 1 | 2005 | 167 | 0.010 |
Why?
| | Chromosomes, Human | 1 | 1984 | 39 | 0.010 |
Why?
| | Hexuronic Acids | 1 | 1984 | 23 | 0.010 |
Why?
| | Glucuronic Acid | 1 | 1984 | 25 | 0.010 |
Why?
| | Polyethylene Glycols | 1 | 1989 | 561 | 0.010 |
Why?
| | Alginates | 1 | 1984 | 43 | 0.010 |
Why?
| | Filtration | 1 | 1984 | 59 | 0.010 |
Why?
| | Freezing | 1 | 1984 | 84 | 0.010 |
Why?
| | Sequence Analysis, DNA | 1 | 2007 | 723 | 0.010 |
Why?
| | Kidney | 8 | 1975 | 1188 | 0.010 |
Why?
| | Culture Techniques | 4 | 1973 | 78 | 0.010 |
Why?
| | Bone Marrow Cells | 1 | 1984 | 267 | 0.010 |
Why?
| | Fetal Blood | 1 | 1985 | 270 | 0.010 |
Why?
| | Transcription, Genetic | 4 | 1977 | 1313 | 0.010 |
Why?
| | RNA, Small Interfering | 1 | 2005 | 535 | 0.010 |
Why?
| | Socioeconomic Factors | 1 | 2007 | 1079 | 0.010 |
Why?
| | Prognosis | 1 | 2010 | 3329 | 0.010 |
Why?
| | Stomatitis, Herpetic | 1 | 1982 | 5 | 0.010 |
Why?
| | Phosphonoacetic Acid | 1 | 1982 | 10 | 0.010 |
Why?
| | Up-Regulation | 1 | 2005 | 808 | 0.010 |
Why?
| | Brain | 1 | 1993 | 2371 | 0.010 |
Why?
| | Disease Models, Animal | 1 | 1991 | 3535 | 0.010 |
Why?
| | Agammaglobulinemia | 1 | 1982 | 30 | 0.010 |
Why?
| | Interleukin-6 | 1 | 2005 | 676 | 0.010 |
Why?
| | NF-kappa B | 1 | 2005 | 641 | 0.010 |
Why?
| | Temperature | 1 | 1984 | 565 | 0.010 |
Why?
| | Ulnar Nerve | 1 | 2001 | 16 | 0.010 |
Why?
| | Administration, Oral | 2 | 1997 | 728 | 0.010 |
Why?
| | Cell Survival | 1 | 1984 | 1021 | 0.010 |
Why?
| | Embryo, Mammalian | 2 | 1973 | 213 | 0.010 |
Why?
| | Ambulatory Care | 1 | 2004 | 478 | 0.010 |
Why?
| | Phytohemagglutinins | 1 | 1980 | 27 | 0.010 |
Why?
| | Serum Albumin | 1 | 2001 | 137 | 0.010 |
Why?
| | Neuroglia | 1 | 2001 | 150 | 0.010 |
Why?
| | Cell Communication | 1 | 1982 | 280 | 0.010 |
Why?
| | Phagocytosis | 1 | 1982 | 350 | 0.010 |
Why?
| | Multicenter Studies as Topic | 1 | 2001 | 249 | 0.010 |
Why?
| | Leukocytes | 1 | 1981 | 276 | 0.010 |
Why?
| | Air Microbiology | 1 | 1980 | 39 | 0.010 |
Why?
| | Nasal Decongestants | 1 | 1999 | 8 | 0.010 |
Why?
| | Immunity, Maternally-Acquired | 1 | 1979 | 18 | 0.010 |
Why?
| | Carbon Isotopes | 4 | 1973 | 111 | 0.010 |
Why?
| | Otorhinolaryngologic Surgical Procedures | 1 | 1999 | 33 | 0.010 |
Why?
| | Immunoglobulins | 1 | 1979 | 143 | 0.010 |
Why?
| | Mitogens | 1 | 1978 | 58 | 0.010 |
Why?
| | Lectins | 1 | 1978 | 42 | 0.010 |
Why?
| | Steroids | 1 | 1999 | 144 | 0.010 |
Why?
| | Bronchopulmonary Dysplasia | 2 | 1993 | 329 | 0.010 |
Why?
| | Cross Infection | 1 | 1980 | 197 | 0.010 |
Why?
| | Rabbits | 1 | 1979 | 733 | 0.010 |
Why?
| | Th2 Cells | 1 | 1998 | 154 | 0.010 |
Why?
| | Amanitins | 1 | 1977 | 4 | 0.010 |
Why?
| | Centrifugation, Density Gradient | 3 | 1971 | 40 | 0.010 |
Why?
| | Erythrocytes | 1 | 1982 | 591 | 0.010 |
Why?
| | Antigen-Antibody Complex | 1 | 1997 | 84 | 0.010 |
Why?
| | Interleukin-10 | 1 | 1998 | 299 | 0.010 |
Why?
| | Combined Modality Therapy | 1 | 1999 | 1121 | 0.010 |
Why?
| | Heart Defects, Congenital | 2 | 1993 | 671 | 0.010 |
Why?
| | Adenoviridae Infections | 1 | 1975 | 15 | 0.010 |
Why?
| | Patient Selection | 1 | 1999 | 641 | 0.010 |
Why?
| | Indicator Dilution Techniques | 1 | 1994 | 9 | 0.010 |
Why?
| | Evidence-Based Medicine | 1 | 1999 | 668 | 0.010 |
Why?
| | Uridine | 2 | 1973 | 29 | 0.010 |
Why?
| | Centrifugation, Zonal | 2 | 1971 | 2 | 0.010 |
Why?
| | Abortion, Therapeutic | 1 | 1974 | 5 | 0.010 |
Why?
| | Rubella virus | 1 | 1974 | 6 | 0.010 |
Why?
| | Cesium | 2 | 1971 | 16 | 0.010 |
Why?
| | Molecular Biology | 2 | 1971 | 56 | 0.010 |
Why?
| | Sucrose | 2 | 1971 | 92 | 0.010 |
Why?
| | Chlorides | 2 | 1971 | 127 | 0.010 |
Why?
| | Microscopy, Electron | 2 | 1990 | 410 | 0.010 |
Why?
| | Pulmonary Fibrosis | 1 | 1975 | 323 | 0.010 |
Why?
| | Complement Fixation Tests | 2 | 1984 | 6 | 0.010 |
Why?
| | Hemagglutination Tests | 1 | 1991 | 7 | 0.010 |
Why?
| | Stress, Psychological | 1 | 1998 | 944 | 0.010 |
Why?
| | Genes | 1 | 1971 | 223 | 0.010 |
Why?
| | Population Surveillance | 1 | 1993 | 392 | 0.010 |
Why?
| | Kidney Transplantation | 1 | 1975 | 541 | 0.010 |
Why?
| | Nonoxynol | 1 | 1989 | 4 | 0.010 |
Why?
| | Latex | 1 | 1989 | 9 | 0.010 |
Why?
| | Suspensions | 1 | 1987 | 30 | 0.000 |
Why?
| | Ribonucleases | 1 | 1987 | 52 | 0.000 |
Why?
| | Chloroquine | 1 | 1987 | 52 | 0.000 |
Why?
| | Deltaretrovirus | 1 | 1986 | 12 | 0.000 |
Why?
| | Binding, Competitive | 1 | 1985 | 193 | 0.000 |
Why?
| | Leukocyte Count | 1 | 1985 | 293 | 0.000 |
Why?
| | Mitosis | 1 | 1985 | 164 | 0.000 |
Why?
| | Histocompatibility Antigens Class II | 1 | 1985 | 352 | 0.000 |
Why?
| | Serologic Tests | 1 | 1983 | 49 | 0.000 |
Why?
| | Histocompatibility Antigens | 2 | 1974 | 98 | 0.000 |
Why?
| | Infusions, Parenteral | 1 | 1982 | 36 | 0.000 |
Why?
| | Genetics, Microbial | 2 | 1971 | 9 | 0.000 |
Why?
| | Liver | 1 | 1988 | 1637 | 0.000 |
Why?
| | Leukemia | 1 | 1983 | 209 | 0.000 |
Why?
| | Hospital Bed Capacity, 300 to 499 | 1 | 1980 | 5 | 0.000 |
Why?
| | Air Movements | 1 | 1980 | 10 | 0.000 |
Why?
| | Hospital Units | 1 | 1980 | 23 | 0.000 |
Why?
| | Boston | 1 | 1980 | 75 | 0.000 |
Why?
| | Communicable Disease Control | 1 | 1980 | 67 | 0.000 |
Why?
| | Methods | 1 | 1978 | 58 | 0.000 |
Why?
| | p-Fluorophenylalanine | 1 | 1976 | 2 | 0.000 |
Why?
| | Cycloheximide | 1 | 1976 | 54 | 0.000 |
Why?
| | Hospitals, Pediatric | 1 | 1980 | 480 | 0.000 |
Why?
| | Inclusion Bodies, Viral | 1 | 1975 | 2 | 0.000 |
Why?
| | Cytoplasm | 1 | 1976 | 255 | 0.000 |
Why?
| | Cadaver | 1 | 1975 | 299 | 0.000 |
Why?
| | Transplantation, Homologous | 1 | 1975 | 377 | 0.000 |
Why?
| | Postoperative Complications | 1 | 1983 | 2128 | 0.000 |
Why?
| | Genetic Code | 1 | 1971 | 20 | 0.000 |
Why?
| | Nucleic Acid Denaturation | 1 | 1971 | 31 | 0.000 |
Why?
| | Chymotrypsin | 1 | 1971 | 16 | 0.000 |
Why?
| | Platinum | 1 | 1971 | 38 | 0.000 |
Why?
| | Molecular Weight | 1 | 1971 | 331 | 0.000 |
Why?
| | DNA Replication | 1 | 1971 | 202 | 0.000 |
Why?
| | Carbon | 1 | 1971 | 156 | 0.000 |
Why?
| | Hot Temperature | 1 | 1971 | 302 | 0.000 |
Why?
| | Lung | 1 | 1975 | 3561 | 0.000 |
Why?
|
|
Levin's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|